Streetbeat News

Price Targets

TYL

JMP Securities analyst Trevor Walsh has reiterated a 'Market Outperform' rating on Tyler Technologies (TYL) and maintained a price target of $490.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:18 pm

TWLO

JMP Securities analyst Patrick Walravens has reiterated a 'Market Outperform' rating on Twilio (TWLO) and maintained a price target of $110.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:15 pm

LCID

TSLA

RBC Capital Markets analyst Tom Narayan has halved Lucid Group's price forecast from $6 to $3 despite its technology being 12%-23% more efficient than Tesla's. The downgrade is due to reactive discussions with OEMs, lower expected licensing penetration, and demand concerns for its sedans. Lucid's Gravity and Mid-size offerings aim to reverse these woes, and its tech could benefit PHEVs amidst the EV slowdown in the U.S. Lucid also adjusted the price of its Lucid Air Pure model to compete with luxury sedans from Mercedes and BMW.

Portfolio Pulse from Nabaparna Bhattacharya

March 08, 2024 | 6:08 pm

MDB

JMP Securities analyst Patrick Walravens has reiterated a 'Market Outperform' rating on MongoDB (MDB) and maintained a price target of $440.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:08 pm

EYPT

HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a price target of $33.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:06 pm

IOT

TD Cowen analyst J. Derrick Wood maintains an Outperform rating on Samsara (NYSE:IOT) and raises the price target from $36 to $45.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:04 pm

ONCY

HC Wainwright & Co. analyst Patrick Trucchio has maintained a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) with a $5 price target, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:04 pm

GPCR

JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Structure Therapeutics (NASDAQ:GPCR), maintaining a $91 price target.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:02 pm

MAT

Analysts have mixed views on Mattel (NASDAQ:MAT), with recent ratings ranging from bullish to indifferent. The average 12-month price target is now $21.71, down from $23.33. Analyst actions include both upgrades and downgrades, reflecting varying perspectives on the company's market position and financial health. Mattel's revenue declined by -15.54% as of December 31, 2023, but it maintains a strong net margin of 9.09% and an exceptional ROE of 7.04%. The company faces challenges with a high debt-to-equity ratio of 1.2.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 6:01 pm

ALIM

HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on Alimera Sciences (NASDAQ:ALIM) and increased the price target from $5 to $6.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:01 pm